AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00621608 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Hyperbaric Oxygen Chamber
Description: Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
Study NCT03633305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypnotics
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.
Study NCT03633305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotics
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.
Study NCT03633305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT
Description: Internet self-help program for insomnia with 6 cores.
Study NCT03633305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face CBT
Description: Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
Study NCT02463201 — intervention group
Intervention type: BEHAVIORAL
Intervention: Weight loss
Study NCT02243202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: 300 mg capsule, taken once daily, orally for 26 weeks.
Study NCT02243202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: 15 mg capsule, taken once daily, orally for 26 weeks.
Study NCT02243202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Canagliflozin
Description: Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
Study NCT02243202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo to Canagliflozin
Description: Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
Study NCT02243202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Phentermine
Description: Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
Study NCT02243202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo to Phentermine
Description: Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
Study NCT03499522 — intervention group
Intervention type: OTHER
Intervention: Observational group
Description: The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~* Numerical scale of pain~* Short Form 36 Health Survey \[SF-36\].~* State-Trait Anxiety Inventory \[STAI\].~* Tampa Scale of Kinesiophofia \[TSK-11SV\].~* Pain catastrophizing scale \[PCS\].~* Coping Strategies Questionnaire \[CSQ\].
Study NCT01718002 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational video
Description: The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
Study NCT03092375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
Description: daily
Study NCT03092375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200Mg Tablet
Description: Weight-based 1000-1200 mg
Study NCT04545567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RocketAP
Description: Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal
Study NCT04545567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USS Virginia
Description: Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion
Study NCT02272907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of saline solution into specimen to test bursting pressure.
Description: A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
Study NCT02272907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of saline solution into specimen to test bursting pressure.
Description: A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
Study NCT02357004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: CR 40 mg daily in addition to normal BP medications
Study NCT02357004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: 12.5 mg daily in addition to normal BP medications
Study NCT03746054 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
Study NCT03746054 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: usual clinical practice
Description: usual clinical practice in each center
Study NCT03063086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A
Study NCT02318043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)
Description: Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
Study NCT02767583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exams
Description: Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
Study NCT03063086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B
Study NCT03063086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C
Study NCT00527033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral
Study NCT03013946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concomitant coaching
Description: The corner stones of the pro-active coaching are as follows:~* Patient education:~  * Information on nature and severity of treatment emergent AEs~ * information about remedies for TEAEs~ * propagation and explanation of tests and treatment decisions~ * Patient instruction on self-care and preventive measures~* Preemptive AE treatment strategies~* Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach
Study NCT00527033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03896009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07 (MoSEIC meloxicam and rizatriptan)
Description: AXS-07 taken once upon onset of a qualifying migraine.
Study NCT03896009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam taken once upon onset of a qualifying migraine.
Study NCT03896009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: Rizatriptan taken once upon onset of a qualifying migraine.
Study NCT03896009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once upon onset of a qualifying migraine.
Study NCT03897062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 20 mg
Description: Placebo controlled double blind suvorexant vs placebo
Study NCT03897062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo controlled double blind suvorexant vs placebo
Study NCT02124889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Internet surveys
Description: Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
Study NCT04098406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
Study NCT05269173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flos gossypii flavonoids tablet
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
Study NCT04098406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was liquid with identical color and taste
Study NCT05269173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flos gossypii flavonoids tablet
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
Study NCT04978974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Program
Description: Stress management program includes different techniques such as relaxation technique, psycho-education, laughing, emotional freedom technique, referenting, cognitive restructuring, rational emotive imagery, time management, anger management, assertiveness and social support
Study NCT02832622 — intervention group
Intervention type: DEVICE
Intervention: MPP
Description: MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
Study NCT02832622 — intervention group
Intervention type: DEVICE
Intervention: BiV/MPP
Description: MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
Study NCT03460457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: Pharmacokinetics/Dynamics Study
Study NCT00003084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin IV on days 1, 15, and 29.
Study NCT00003084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium
Description: Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle.
Study NCT00003084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Oral etoposide twice daily on days 1-14.
Study NCT00003084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
Study NCT00003084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV over 1 hour on day 2.
Study NCT00003084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: IV on days 8, 22, and 36.
Study NCT01808625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HYPERBARIC OXYGEN STIMULATION
Description: 30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
Study NCT04633447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.
Study NCT04633447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously.
Study NCT02916602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1401
Description: amlodipine, Losartan, Chlorthalidone FDC
Study NCT02916602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0605
Description: amlodipine, Losartan FDC
Study NCT01461382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Desks
Description: Treadmill Desk were installed in subjects personal workspace.
Study NCT01461382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Desks
Description: Treadmill desks were installed in subjects personal workspace six months after phase I started.
Study NCT01450722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bypass surgery, stent placement
Description: bypass surgery, stent placement
Study NCT01450722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent placement
Description: placement of paclitaxel eluting stent in long superficial femoral artery obstruction
Study NCT03326960 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
Study NCT03326960 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
Study NCT03326960 — intervention group
Intervention type: DRUG
Intervention: Desflurane
Description: Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
Study NCT01533363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled hemorrhoidopexy
Study NCT01533363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Milligan Morgan
Study NCT02073916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: antibody-drug conjugate of trastuzumab and emtansine
Study NCT02073916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dual tyrosine kinase inhibitor (HER2 and EGFR)
Study NCT02073916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
Study NCT02282397 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor
Description: RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
Study NCT02106130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: oral administration, 3 times/day
Study NCT02106130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: oral administration, 3 times/day
Study NCT00521144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV
Study NCT00521144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00521144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03586752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard program
Description: 60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
Study NCT02574897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic symptom survey
Description: Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
Study NCT02574897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blinded Electronic Symptom Survey
Description: Standard of care daily clinician interviews with blinded symptom surveys
Study NCT03320304 — intervention group
Intervention type: DEVICE
Intervention: Vagal Nerve Simulation (VNS) Therapy
Description: A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
Study NCT04647396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)
Description: Implementation of the KDIGO bundle for at least 12 hours~1. discontinuation of all nephrotoxic drugs when possible~2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~3. close monitoring of serum creatinine, fluid balance and urinary output~4. avoidance of hyperglycemia~5. considerations of alternatives to radiocontrast agents~6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~7. avoidance of HES, gelatin, and chlorid-rich solutions
Study NCT04117646 — intervention group
Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: Subjects respond to the translated questionnaire twice at 15 days apart.
Study NCT03346681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
Study NCT04501640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral adminstration
Study NCT02173522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate artery embolization (PAE)
Description: Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
Study NCT03270852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced reality
Description: This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro.
Study NCT03270852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Enhanced reality
Description: Identical rehabilitation without enhanced reality
Study NCT04339985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: Topical